Ogremorphin (OGM, OGM8345) represents a pioneering small-molecule inhibitor that selectively targets GPR68, demonstrating high specificity with an IC50 value of 0.71 µM. As a first-in-class compound, it offers unique therapeutic potential by precisely modulating GPR68 activity.